Greenwich Lifesciences Inc. Overview

Greenwich Lifesciences, Inc., a biotechnology company operating within the health care sector, is headquartered in Stafford, United States. The company is dedicated to developing and discovering treatments for cancer, with a particular focus on serving patients in Texas. Greenwich Lifesciences is publicly traded on the Nasdaq stock exchange.

Financial Snapshot

As of July 31, 2025, Greenwich Lifesciences reported a close price of $11.09. The company’s stock has experienced significant fluctuations over the past year, reaching a 52-week high of $16.50 on September 8, 2024, and a 52-week low of $8.06 on April 6, 2025. The market capitalization of the company stands at $146,250,000 USD. However, the company’s price-to-earnings ratio is currently at -8.66, indicating a challenging financial performance.

Company Mission and Focus

Greenwich Lifesciences is committed to advancing cancer treatment through innovative research and development. The company’s mission is centered on discovering new therapies that can improve patient outcomes, particularly for those residing in Texas. For more detailed information about their ongoing projects and initiatives, interested parties can visit their official website at www.greenwichlifesciences.com .

Conclusion

Greenwich Lifesciences, Inc. continues to navigate the complexities of the biotechnology sector with a steadfast focus on cancer treatment. Despite recent financial challenges, as reflected in its negative price-to-earnings ratio, the company remains dedicated to its mission of developing life-saving treatments. Investors and stakeholders are encouraged to monitor the company’s progress and developments through its Nasdaq listings and official communications.